Porphyrin DeriVatiVes of Steroids
J. Am. Chem. Soc., Vol. 118, No. 22, 1996 5205
tions of spectra were carried out with a software developed in house:
DFT (discrete Fourier transform) procedure.
J ) 8.06 Hz), 8.42, 8.49 (2d, 4 H, J ) 8.06 Hz), 8.78-8.90 (m, 16 H);
FAB-MS m/z 1473 (M + H+); FAB-HRMS m/z for C109H89N8O4 calcd
1573.7010, found 1573.7030.
5-(4′-Carboxymethylphenyl)-10,15,20-triphenylporphin (5). To
a mixture of 4-carboxymethylbenzaldehyde (2, 4.104 g, 25 mmol),
benzaldehyde (3, 7.960 g, 75 mmol), and Zn(OAc)2 (5.480 g, 25 mmol)
in propionic acid (500 mL) was added pyrrole (4, 6.710 g, 100 mmol)
at 100 °C within 1 h under vigorous stirring. The resulting dark solution
was refluxed for further 4 h and then cooled to room temperature. The
solvent was evaporated (15 Torr, 80 °C ), and the solid residue was
subjected to CC (SiO2, 40 g, 7 × 45 cm, CH2Cl2). All product
containing fractions were collected. The volume was reduced to 100
mL (15 Torr), and pyridine (2 mL) and an excess of DDQ (2 g) were
added at room temperature. The resulting mixture was refluxed until
the oxidation was complete (1 h), monitored by the disappearance of
the absorption at 626 nm. Cooled to room temperature, the solution
was extracted with 18% aqueous HCl solution (3 × 100 mL),
neutralized with saturated aqueous NaHCO3 solution (3 × 100 mL),
washed with brine (1 × 100 mL), dried (Na2SO4), and evaporated (15
Torr) to give 11.5 g of black-purple crude product. Purification by
CC (SiO2, 30 g, 3.5 × 30 cm, CH2Cl2) yielded pure 5 (1.23 g, 7.5%)
as deep purple crystals. TLC (CH2Cl2) Rf 0.74; mp >300 °C; UV-
vis (MeCN) 645 (4600), 588 (4500), 545 (7000), 511 (15 900), 413
(353 000), 365 (sh, 33 000); UV-vis (CH2Cl2) 645 (4400), 589 (4450),
549 (6900), 514 (15 700), 418 (371 000), 365 (sh, 31 500); IR (CCl4)
5r-Androstane-3r,17â-diol Bis(p-dimethylaminobenzoate) (7c).
A solution of 7a (4.0 mg, 13.6 µmol), p-dimethylaminobenzoyl triazol4c
(20 mg, 92.6 µmol), and DBU (5.4 mg, 35.4 µmol) in absolute CH2-
Cl2 (1 mL) was stirred at room temperature for 24 h, diluted with CH2-
Cl2 (20 mL), extracted with a solution of saturated aqueous NH4Cl (3
× 20 mL), washed with brine (2 × 20 mL), dried (Na2SO4), and
evaporated (15 Torr) to give 10.0 mg (132%) of crude product, which
was purified by PTLC (SiO2, CH2Cl2, Rf 0.10, 2×) to yield pure 7c
(5.3 mg, 75%) as a slightly yellow powder. TLC (CH2Cl2/MeOH 20:
1) Rf 0.33; mp 218-220 °C; UV-vis (CH2Cl2) 310 (53 200); IR (CCl4)
2932, 2863, 1705, 1547, 1252, 1217, 1107, 1068, 1004, 978; 1H NMR
(400 MHz, CDCl3) δ 0.80-2.30 (several m, 22 H), 0.86, 0.93 (2s, 2
CH3), 3.04, 3.05 (2s, N(CH3)2), 4.80 (t, 1 H, J ) 9.07 Hz, H-C(17)),
5.22-5.24 (m, 1 H), 6.65, 6.67 (2d, 4 H, J ) 5.41 Hz), 7.91, 7.93 (2d,
4 H, J ) 5.41 Hz); FAB-MS m/z 586 (100, M+); FAB-HRMS m/z for
C37H50N2O4 calcd 586.3771, found 586.3775.
5r-Androstane-3â,17r-diol Bis(p-[10′,15′,20′-triphenyl-5′-por-
phyrinyl]benzoate) (8b). Following the procedure for 6b, 8a (3.6 mg,
12.33 µmol) was converted to 19.0 mg (130%) of crude product, which
was purified by CC (SiO2, 2 × 25 cm, 20 g, CH2Cl2, Rf 0.66) to yield
pure 8b (11.1 mg, 75%) as a deep purple powder. TLC (CH2Cl2) Rf
0.69; UV-vis (CH2Cl2) 645 (8200), 589 (8300), 549 (12 800), 514
1
1718, 1285; H NMR (400 MHz, CDCl3) δ -2.64 (s, 2 H, exchange
1
with D2O), 4.13 (s, 3 H), 7.75-7.80 (m, 9 H), 8.22-8.25 (m, 6 H),
8.32 (d, 2 H, J ) 8.14 Hz), 8.46 (d, 2 H, J ) 8.14 Hz), 8.85-8.89 (m,
8 H); FAB-MS m/z 673 (M + H+); FAB-HRMS m/z for C46H33N4O2,
calcd 673.2603, found 673.2598; CD (MeOH) -; CD (CH2Cl2) -.
5-(4′-Carboxyphenyl)-10,15,20-triphenylporphin (TPP, 1). To a
solution of 5 (1.10 g, 1.63 mmol) in EtOH (50 mL) was added 2 N
NaOH (100 mL), and the suspension was refluxed for 4 h. Cooled to
room temperature, the solvent was decanted, and the crude product
was washed with water (2 × 50 mL), MeOH (3 × 20 mL), and hexane
(2 × 50 mL). Evaporation (15 Torr and 0.01 Torr) gave anal. pure 1
(922 mg, 86%) as a deep purple powder. Mp >300 °C; UV-vis
(MeOH) 645 (4600), 588 (4500), 545 (7000), 511 (15 900), 413
(29 200), 418 (690 000); H-NMR (400 MHz, CDCl3) δ -2.67 (s, 2
H, exchange with D2O), 0.93-2.50 (several m, 22 H), 0.96, 1.02 (2s,
2 CH3), 5.09-5.16 (m, 1 H), 5.27 (d, 1 H, J ) 6.23 Hz), 7.74-7.81
(m, 18 H), 8.21-8.26 (m, 12 H), 8.29, 8.36 (2d, 4 H, J ) 8.04 Hz),
8.43, 8.49 (2d, 4 H, J ) 8.06 Hz), 8.79-9.00 (m, 16 H).
5r-Androstane-3â,17â-diol Bis(p-[10′,15′,20′-triphenyl-5′-porphy-
rinyl]benzoate) (9b). Following the procedure for 6b, 9a (1.1 mg,
7.6 µmol) was converted to 7.0 mg (118%) of crude product, which
was purified by PTLC (SiO2, CH2Cl2, Rf 0.35) to yield pure 9b (3.8
mg, 64%) as a deep purple powder. TLC (CH2Cl2) Rf 0.35; UV-vis
(CH2Cl2) 645 (8200), 589 (8300), 549 (12 800), 514 (29 200), 418
1
(690 000); H NMR (400 MHz, CDCl3) δ -2.63 (s, 2 H, exchange
1
(353 000), 365 (sh, 33 000); IR (CCl4) 3444, 1639, 1211; H NMR
with D2O), 0.93-2.50 (several m, 22 H), 0.97, 1.05 (2s, 2 CH3), 5.02
(t, 1 H, J ) 8.42 Hz), 5.11-5.19 (m, 1 H), 7.73-7.85 (m, 18 H),
8.16-8.22 (m, 12 H), 8.34, 8.36 (2d, 4 H, J ) 8.04 Hz), 8.44 (d, 8 H,
J ) 8.06 Hz), 8.80-9.00 (m, 16 H).
(400 MHz, CDCl3/CD3OD 4:1) δ -3.00 to -2.00 (br s, ca. 2 H), 7.74-
7.80 (m, 9 H), 8.21-8.24 (m, 6 H), 8.35 (d, 2 H, J ) 8.05 Hz), 8.51
(d, 2 H, J ) 8.05 Hz), 8.81-8.83 (m, 8 H); FAB-MS m/z 659 (M +
H+); FAB-HRMS m/z for C45H31N4O2, calcd 659.2446, found 659.2457.
5r-Cholestane-3â,6r-diol Bis(p-[10′,15′,20′-triphenyl-5′-porphy-
rinyl]benzoate) (6b). To a solution of 1 (24.4 mg, 37.1 µmol), EDC
(7.1 mg, 37.1 µmol), and DMAP (4.0 mg, 37.1 µmol) in absolute CH2-
Cl2 (1 mL) was added (room temperature) a solution of 6a (5 mg, 12.4
µmol) in CH2Cl2 (1 mL). The mixture was stirred (room temperature,
12 h), diluted with CH2Cl2 (20 mL), extracted with a solution of
saturated aqueous NH4Cl (3 × 20 mL), washed with brine (2 × 20
mL), dried (Na2SO4), and evaporated (15 Torr) to give 29 mg (139%)
of crude product, which was purified by CC (SiO2, 2 × 25 cm, 20 g,
CH2Cl2/hexane 3:1, Rf 0.36) to yield pure 6b (16.3 mg, 78%) as a deep
purple powder. TLC (CH2Cl2/hexane 3:1) Rf 0.36; mp >300 °C; UV-
vis (CH2Cl2) 645 (8200), 589 (8300), 549 (12 800), 514 (29 200), 418
(690 000); IR (CCl4) 2949, 2880, 1713, 1547, 1252, 1218, 1110, 1068,
5r-Androstane-3â,17â-diol Bis(p-dimethylaminobenzoate) (9c).
Following the procedure for 7c, 9a (4.0 mg, 13.6 µmol) was converted
to 7.5 mg (100%) of crude product, which was purified by PTLC (SiO2,
CH2Cl2/MeOH 40:1 Rf 0.62) to yield pure 9c (5.8 mg, 77%) as a slightly
yellow powder. TLC (CH2Cl2/MeOH 40:1) Rf 0.62; mp 221-224 °C;
UV-vis (CH2Cl2) 310 (53 200); 1H NMR (400 MHz, CDCl3) δ 0.80-
2.30 (several m, 22 H), 0.90, 0.93 (2s, 2 CH3), 3.05 (s, 2 N(CH3)2),
4.80 (t, 1 H, J ) 9.07 Hz), 4.85-4.94 (m, 1 H), 6.65, 6.67 (2d, 4 H,
J ) 5.41 Hz), 7.90, 7.93 (2d, 4 H, J ) 5.41 Hz).
1(R),2(R)-trans-Cyclohexanediol Bis(p-[10′,15′,20′-triphenyl-5′-
porphyrinyl]benzoate) (12b). To a solution of 1 (15 mg, 22.8 µmol),
EDC (7.1 mg, 37.1 µmol), and DMAP (4.0 mg, 37.1 µmol) in absolute
CH2Cl2 (2 mL), a solution of 12a (1.3 mg, 11.3 µmol) in CH2Cl2 (1
mL) was added (room temperature). The mixture was refluxed (4 h),
diluted with CH2Cl2 (20 mL), extracted with a solution of saturated
aqueous NH4Cl (3 × 20 mL), washed with brine (2 × 20 mL), dried
(Na2SO4), and evaporated (15 Torr) to give 15 mg (95%) of crude
product, which was purified by CC (SiO2, 2 × 25 cm, 20 g, CH2Cl2,
Rf 0.56) to yield pure 12b (8.5 mg, 54%) as a deep purple powder.
TLC (CH2Cl2) Rf 0.56; mp >300 °C; UV-vis (MeCN) 644 (7100),
593 (8000), 551 (20 600), 513 (26 700), 419 (690 500); IR (CCl4) 2918,
2857, 1717, 1598, 1550, 1348, 1269, 1251, 1110, 1097, 1001, 961;
1H-NMR (400 MHz, CDCl3) δ -2.70 (s, 2 H, exchange with D2O),
1.2-2.5 (several m, 8 H), 5.57-5.63 (br m, 2 H), 7.50-7.62, 7.69-
7.80 (2m, 18 H), 8.07-8.12, 8.18-8.22 (2m, 12 H), 8.29-8.54 (several
d-lk m, 8 H), 8.68-8.99 (several m, 16 H); FAB-MS m/z 1397 (M +
H+); FAB-HRMS m/z for C96H69N8O4 calcd 1397.5440, found 1397.5447.
5r-Androstane-17â-diphenylmethylsilyloxy-3-one (15). A solu-
tion of stanolone 14 (480 mg, 1.655 mmol), DPMSCl (385 mg, 1.67
mmol), and imidazole (113 mg, 1.67 mmol) in absolute CH2Cl2 (50
mL) was stirred at room temperature for 15 h, diluted with CH2Cl2 (50
1
1000, 978; H NMR (400 MHz, CDCl3) δ -2.64 (s, 2 H, exchange
with D2O), 0.74-2.55 (several m, 44 H), 5.23-5.34 (br m, 2 H), 7.67-
7.83 (2m, 18 H), 8.21-8.29 (m, 12 H), 8.31, 8.36 (2d, 4 H, J ) 8.06
Hz), 8.48, 8.50 (2d, 4 H, J ) 8.06 Hz), 8.85-8.89 (m, 16 H); FAB-
MS m/z 1685 (M + H+); FAB-HRMS m/z for C117H105N8O4 calcd
1685.8280, found 1685.8260.
5r-Androstane-3r,17â-diol Bis(p-[10′,15′,20′-triphenyl-5′-por-
phyrinyl]benzoate) (7b). Following the procedure for 6b, 7a (7.6 mg,
11.5 µmol) was converted to 12.0 mg (135%) of crude product, which
was purified by CC (SiO2, 2 × 25 cm, 20 g, CH2Cl2, Rf 0.69) to yield
pure 7b (6.5 mg, 73%) as a deep purple powder. TLC (CH2Cl2) Rf
0.69; mp >300 °C; UV-vis (CH2Cl2) 645 (8200), 589 (8300), 549
(12 800), 514 (29 200), 418 (690 000); IR (CCl4) 2940, 2875, 1710,
1547, 1252, 1218, 1110, 1068, 1000, 978; 1H NMR (400 MHz, CDCl3)
δ -2.64 (s, 2 H, exchange with D2O), 0.93-2.50 (several m, 22 H),
0.99, 1.12 (2s, 2 CH3), 5.02 (t, 1 H, J ) 8.42 Hz), 5.49-5.52 (m, 1
H), 7.74-7.79 (m, 18 H), 8.21-8.25 (m, 12 H), 8.29, 8.36 (2d, 4 H,